Herbal medicine stock with no sales rallies 64,000%
[NEW YORK] A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year and yet, the company itself has made zero revenue – much less turned a profit.
The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth more than US$20 billion in market value. A year ago, the stock had a market capitalisation of just US$53 million. This is despite the company having a net loss of US$4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year.
Earlier this month the company said its board approved a 38-for-1 stock split. When the split took effect on Monday (Jun 16), shares rose as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts.
Shares of the company have been on a bizarre, 640-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission (SEC).
A representative for Regencell did not immediately respond to a Bloomberg News request for comment.
Incorporated in the Cayman Islands, the firm aims to treat neurological disorders such as ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components'.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing.
The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid-19 symptoms within six days, although the results were yet to be peer-reviewed.
The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering (IPO), the SEC filing showed. It said its gross proceeds from its IPO were US$21.85 million, with additional net proceeds of US$2.85 million from the issue of the over allotment shares and exercise of 325,000 shares.
One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6 per cent of shares, compared to Apple – which has about 98 per cent available – and Tesla's 87 per cent.
Insiders own the remaining Regencell shares, with chief executive officer Yat-Gai Au's ownership accounting for 86 per cent, according to holding data compiled by Bloomberg. BLOOMBERG
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
37 minutes ago
- Business Times
DayOne seeks US$1 billion private credit for data centre expansion
[SINGAPORE] DayOne Data Centers Singapore is seeking a private credit loan of at least US$1 billion to fund its expansion plans, according to people familiar with the matter. The proposed loan, which can be upsized by an additional US$250 million, is set to pay an interest of 9.5 per cent to 10 per cent, the people said, who asked not to be identified discussing private matters. The financing will have a four-year tenor and may include a payment-in-kind piece, they said. The deal is still in early stages and could be subject to change, the people said. Singapore-headquartered DayOne did not respond to a request for comment. Artificial intelligence advances are fuelling demand for data centre fundraisings in Asia, a region that has seen a series of record breaking loans. Some of these deals go beyond the traditional bank lending space, which is struggling to keep up with the rapid pace of expansion for data storage and processing. Demand for data centre expansion in Asia is set to grow by about 32 per cent a year in the region through 2028, according to real estate services firm Cushman and Wakefield, outpacing expected growth of 18 per cent in the US. Last week, DayOne, formerly the international arm of GDS Holdings, secured RM15 billion (S$4.5 billion) of multicurrency loans to support its green data centres in Malaysia's Johor state, Bloomberg News reported. The facility, which is its biggest-ever borrowing, is also among the largest syndicated financings for the sector by a borrower in Asia. BLOOMBERG
Business Times
37 minutes ago
- Business Times
SoftBank sells T-Mobile stake for US$4.8 billion to bet on AI
[NEW YORK] SoftBank Group raised around US$4.8 billion through a sale of T-Mobile US shares, a move that helps fund the Japanese company's grandiose plans for artificial intelligence. The Tokyo-based technology group sold 21.5 million T-Mobile shares for US$224 each – pricing at the bottom of the US$224 to US$228 range – in an unregistered overnight block sale, according to the final terms of the deal seen by Bloomberg News. The offering, which Bloomberg reported earlier, represents a discount of 3 per cent to T-Mobile US' Monday closing price of US$230.99 per share. SoftBank founder Masayoshi Son is ramping up investments aimed at making AI reasoning superior to humans'. He's overseeing plans to put down as much as US$30 billion in OpenAI and is also working with the ChatGPT creator to ferry hundreds of billions of dollars into data centres and related infrastructure around the world under the Stargate banner. SoftBank's original plans for debt financing had snagged on uncertainties around US tariffs. T-Mobile shares fell 3.9 per cent in extended trading, while SoftBank's shares rose 2.1 per cent in Tokyo. A representative of SoftBank declined to comment. Representatives of T-Mobile did not immediately respond to a request for comment outside normal business hours. The deal is the biggest US share sale since Toronto-Dominion Bank sold a US$13.1 billion stake in brokerage firm Charles Schwab in February. Sales of new and existing shares in US-listed companies reached US$91.4 billion in the year to date, up from US$75.9 billion in the same period a year ago, data compiled by Bloomberg show. The T-Mobile stake sale would be the latest example of Son tapping past investment successes – such as an early bet on Alibaba Group Holding that's yielded thousands-fold returns – to fund new ventures. SoftBank received T-Mobile shares with the completion of the US telecom company's US$26.5 billion acquisition of Sprint in April 2020. Later that year, SoftBank substantially reduced its stake in T-Mobile via a US$21 billion deal that helped pay for a record buyback of SoftBank's shares. The stake offered represents about 1.9 per cent of T-Mobile's outstanding shares, according to Bloomberg calculations. SoftBank owned 85.4 million shares or 7.5 per cent of T-Mobile as of March 31, according to its annual report. Deutsche Telekom is T-Mobile's largest shareholder with a 59 per cent stake, according to a June 12 filing with the US Securities and Exchange Commission. BLOOMBERG
AsiaOne
an hour ago
- AsiaOne
New Zealand PM to discuss trade, tourism and security in first visit to China, World News
BEIJING/WELLINGTON — New Zealand's Prime Minister Christopher Luxon will visit China from Tuesday (June 17), looking to foster trade ties and woo tourists and students, although thorny issues of security and defence will figure on his agenda in meetings with top leaders. Making his first visit to China since becoming prime minister in November 2023, Luxon will arrive in the financial hub of Shanghai before heading to Beijing for meetings on Friday with President Xi Jinping and Premier Li Qiang, his office said. "It's all part of our plan to grow our economy — creating more jobs, lifting wages, and putting more money in your back pocket," Luxon said in an Instagram post as he set off. The visit comes as Beijing's growing influence in the Pacific during the last few years has alarmed many Western nations whose traditionally stronger security foothold there is being challenged. "There are a whole bunch of issues and challenges in the relationship," said Jason Young, director of the New Zealand Contemporary China Research Centre at Victoria University, while adding that both sides agree they have significant interests. New Zealand aired concerns in February, for instance, when the Cook Islands, within its constitutional ambit, signed pacts, such as one on co-operation on the economy, infrastructure and seabed mining, with China, without consulting it first. The presence of a Chinese People's Liberation Army Navy task force in the Tasman Sea and Chinese activity in the Pacific also pose challenges for the relationship, Young added. Significant interests Trade and travel have proved less fractious areas for the two countries, however. The first developed nation to sign a free trade deal with Beijing in 2008, New Zealand counts dairy, meat and wood products as its largest items of export to China. Tourism and education are major services sectors. The Pacific country's exports to China in 2024 stood at NZ$20.85 billion (S$16.22 billion), made up of NZ$17.75 billion in goods and NZ$3.1 billion in services, the foreign ministry says on its website. Chinese tourists are the third-largest group of international visitors to New Zealand, though their numbers are still nearly a fifth lower than in 2019, before the Covid-19 pandemic, official data shows. On the weekend, New Zealand said it would start in November a 12-month trial of visa waivers for Chinese passport holders arriving from Australia with visas valid for its neighbour, reciprocating China's visa-free policy for New Zealanders last year. Luxon, who has called China "a vital part" of his Pacific nation's economic story, has told domestic media that based on the "mature relationship" with Beijing, he expects talks during his four-day visit to cover topics of security and defence. "The challenging global outlook makes it vital that we are sharing perspectives and engaging China on issues that matter to New Zealand," his office said in a statement last week. The leaders of the two countries previously met on the sidelines of November's APEC summit in Peru, while Li visited New Zealand in June last year. Wellington has historically taken a more conciliatory approach towards China than Australia or its other partners in the Five Eyes security arrangement. But in recent years it has become more vocal on issues such as human rights, the international rules-based order and potential militarisation of the Pacific. In June 2023, then Prime Minister Chris Hipkins visited Beijing, prior to Luxon. [[nid:719163]]
